AN2 Therapeutics (ANTX) Enterprise Value (2022 - 2026)

AN2 Therapeutics (ANTX) has reported Enterprise Value for 6 consecutive years, with -$85.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 27.18% year-over-year to -$85.3 million; the TTM figure through Mar 2026 stood at -$85.3 million (down 27.18% YoY), while the FY2025 annual figure was -$58.0 million, up 30.64% from the prior year.
• Enterprise Value retreated to -$85.3 million in Q1 2026 per ANTX's latest filing, from -$58.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$58.0 million in Q4 2025 and bottomed at -$123.8 million in Q3 2023.
• Historically, Enterprise Value has averaged -$92.8 million across 5 years, with a median of -$95.2 million in 2023.
• Annual changes were most pronounced in 2022 — Enterprise Value sank 64.04% — and 2025, when it jumped 41.29%.
• AN2 Therapeutics' Enterprise Value stood at -$96.1 million in 2022, then declined by 11.7% to -$107.3 million in 2023, then increased by 22.07% to -$83.6 million in 2024, then soared by 30.64% to -$58.0 million in 2025, then sank by 47.05% to -$85.3 million in 2026.
• Business Quant data shows ANTX's Enterprise Value at -$85.3 million in Q1 2026, -$58.0 million in Q4 2025, and -$61.9 million in Q3 2025.